Back

MicroRNA-mediated control of cardiac fibrosis: unraveling key players and mechanisms through functional genomics screenings

12 April 2024 (08:30 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity, cardiac fibrosis and metabolic cardiomyopathy Fibrosis CBS PREMIUM ACCESS Frontiers in CardioVascular Biomedicine 2024 Council on Basic Cardiovascular Science

About the speaker

Photo
Doctor Miguel Mano

CNC - Center for Neuroscience and Cell Biology, Coimbra (Portugal)

3 More presentations in this session

Presentation thumbnail
Innovative models for cardiotoxicity assessment in human pluripotent stem cell-derived cardiomyocytes that enable clinically relevant treatment regimen
Assistant Professor V. Schwach (Enschede, NL)
Abstract
Presentation thumbnail
The structural remodeling of the mitochondrial Ca2+ uniporter complex underlies its functional impairment during metabolic cardiomyopathy.
Mr M. Panel (Montpellier, FR)
Abstract
Presentation thumbnail
Prior cardiac ischemic injury exacerbates immune checkpoint inhibitor-induced cardiotoxicity
Doctor T. Gergely (Budapest, HU)
Abstract

Access the full session

Session thumbnail
Cardiotoxicity, cardiac fibrosis and metabolic cardiomyopathy

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2024

12 April - 14 April 2024
You may be interested in
thumbnail
Congress Presentation
Heart failure in the era of single-nuclei and spatial OMICs
thumbnail
Congress Presentation
Quantitative molecular imaging of cardiac fibrosis and response to treatment using a novel collagen III-specific MR imaging probe
thumbnail
Congress Presentation
How do we assess fibrosis in athletic individuals? current practice and novel advances

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources